WILEX announces planned change to Executive Management Board
Munich, 7 August 2012. WILEX AG (ISIN DE0006614720 / WL6 / FWB) announced a planned change in the composition of the Executive Management Board. Peter Llewellyn-Davies, Chief Financial Officer of WILEX AG, will leave the company upon the expiration of his contract after six successful years on the Executive Management Board to take up new professional challenges. Mr. Llewellyn-Davies will however act as an advisor for WILEX AG and continue to support the company. Mr Llewellyn-Davies will fully manage and complete the capital measure announced by WILEX AG on 3 August 2012.
“Mr Llewellyn-Davies has made important contributions to the development of WILEX AG since joining the company prior to its IPO in 2006. We would like to thank him very much for his collaboration, which was both constructive and successful, and wish him great success in realizing his objectives”, said Professor Christof Hettich, Chairman of the Supervisory Board, acknowledging the achievements of Mr. Llewellyn-Davies.
Mr Llewellyn-Davies will be succeeded by Dr Jan Schmidt-Brand, who is currently the Managing Director of WILEX’s subsidiary Heidelberg Pharma GmbH effective 1 September 2012. He holds a doctorate in law and was CEO/CFO of the former Heidelberg Pharma AG until the company was acquired by WILEX AG. From 1997 to 2001, he was Managing Director of the Austrian BASF-Pharma subsidiary, EBEWE Arzneimittel GmbH, where his responsibilities included finance and controlling. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department with a general commercial power of attorney (“Prokurist”). Dr Schmidt-Brand is a member of the Board of BioDeutschland and Head of the Finance and Tax working group.
Katja Arnold (CIRO)
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors [at] wilex.com
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company has a broad portfolio of diagnostic and therapeutic products for the specific detection and targeted treatment of various types of cancer. WILEX’s therapeutic product candidates are based on antibodies (RENCAREX® in Phase III) and small molecules (MESUPRON® in Phase II, WX-554 in Phase Ib/II and WX-037 in preclinical development). In the field of diagnostics, REDECTANE® is an antibody-based, imaging in vivo diagnostic agent that is currently in a Phase III programme. WILEX’s US subsidiary WILEX Inc. in Cambridge, MA, markets a portfolio of research use only tests and in vitro diagnostic agents under the brand Oncogene Science, which are used as companion diagnostics for clinical trials and therapy monitoring. The wholly owned subsidiary Heidelberg Pharma GmbH offers an attractive and highly promising antibody drug conjugate technology platform and preclinical contract research services. The business model of WILEX comprises research, technology, product development and commercialisation. WILEX’s customers and partners include leading international pharmaceutical companies.
Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.